Cabozantinib for advanced neuroendocrine tumors after prior treatment
Part of Cancer clinical trials.
This study tests cabozantinib, a targeted therapy that blocks tumor growth, in people with advanced neuroendocrine tumors who have already tried other treatments. It may offer a new option if your doctor plans to use this drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your doctor has already decided to start cabozantinib for your neuroendocrine tumor (a type of cancer that grows in hormone-making cells).
- Your tumor is well-differentiated (not very aggressive) and has spread or cannot be removed by surgery.
- You have had at least one cancer treatment in the past besides somatostatin analogs (a specific type of hormone therapy).
- You are not currently in another clinical trial, and have not been in one in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a different dosing schedule of cabozantinib (a cancer medicine) for metastatic kidney cancer and certain neuroendocrine tumors. It aims to see if the timing and schedule can work well for people with advanced disease.
This study tests an immunotherapy drug (CTX-471) for people with a specific type of advanced neuroendocrine tumor that has grown after chemotherapy. The goal is to see if the drug can help shrink or control the tumor.
This trial studies whether cabozantinib plus lanreotide can slow or shrink gastroenteropancreatic neuroendocrine tumors that have gotten worse despite previous treatments. If you qualify, you’ll be closely monitored for tumor response and side effects.
This Phase 2 study tests whether combining cabozantinib with temozolomide can control advanced lung or gastrointestinal neuroendocrine tumors that have grown after prior treatments. It also closely monitors safety, including blood counts, organ function, and other side effects.
This study tests a new drug, cabozantinib, for people with liver cancer that has grown despite previous treatment with atezolizumab and bevacizumab. The goal is to see if this drug can help control the cancer.
This trial studies cabozantinib given after standard treatment to try to keep high-risk pediatric solid tumors from coming back or getting worse. It is offered to children and young adults whose cancer has not fully disappeared but is not progressing at the start of this maintenance phase.
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.